Posts tagged hematologic cancer
Cellectar Biosciences refocusing on therapeutics

After completing a strategic review of its cancer therapeutic and cancer diagnostic assets, Cellectar Biosciences (NASDAQ:CLRB) has refocused the company on its phospholipid ether drug conjugate (PDC) platform and cancer-targeting delivery of oncologic payloads.

“We were previously focused on advancing our diagnostic assets, with no plan to take advantage of our cancer therapeutics beyond radiotherapeutics,” newly appointed president and CEO, Jim Caruso, says in an interview with BioTuesdays.com.

“We believe our PDC platform has the potential for significant value creation and as a result, we plan to seek collaborators to complete development of our diagnostic imaging agents,” he adds.

Read More